Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform

To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5°C or higher at...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Public health (London) 2006-11, Vol.120 (11), p.1081-1087
Hauptverfasser: Agtini, M.D., Ochiai, R.L., Soeharno, R., Lee, H.J., Sundoro, J., Hadinegoro, S.R., Han, O.P., Tana, L., Halim, F.X.S., Ghani, L., Delima, Lestari, W., Sintawati, F.X., Kusumawardani, N., Malik, R., Santoso, T.S., Nadjib, M., Soeroso, S., Wangsasaputra, F., Ali, M., Ivanoff, B., Galindo, C.M., Pang, T., Clemens, J.D., Suwandono, A., Acosta, C.J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1087
container_issue 11
container_start_page 1081
container_title Public health (London)
container_volume 120
creator Agtini, M.D.
Ochiai, R.L.
Soeharno, R.
Lee, H.J.
Sundoro, J.
Hadinegoro, S.R.
Han, O.P.
Tana, L.
Halim, F.X.S.
Ghani, L.
Delima
Lestari, W.
Sintawati, F.X.
Kusumawardani, N.
Malik, R.
Santoso, T.S.
Nadjib, M.
Soeroso, S.
Wangsasaputra, F.
Ali, M.
Ivanoff, B.
Galindo, C.M.
Pang, T.
Clemens, J.D.
Suwandono, A.
Acosta, C.J.
description To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5°C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail. During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme. This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.
doi_str_mv 10.1016/j.puhe.2006.06.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68988095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0033350606001661</els_id><sourcerecordid>68988095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-91da7e39ccf8736802161fef53b45f943a2dcb22a373b30cbeb3245dd608d253</originalsourceid><addsrcrecordid>eNp9UV2r1DAQDaJ416t_wAfJk092nSRt2oIvcvFj5aIvF19Dmkxt1m5Sk3Rxf4z_1ZYt-CYcmGHmnAMzh5CXDPYMmHx73E_zgHsOIPcroHlEdqysZVFJJh-THYAQhahA3pBnKR0BgNeiekpuWA1QcQ478ufgcwx2Ns7_oN8dncJ4SdqYQUdnkebLNARnaY9njPS8LJxfpoFO0Z10vNBkhhBGagY32oieOk-_hpgH-kX_1DHrN_TgbfCY3NKenabaU_ztUkafN3HR6YR2M9fZBU-nUec-xNNz8qTXY8IXW70lDx8_PNx9Lu6_fTrcvb8vjKjKXLTM6hpFa0zf1EI2wJlkPfaV6Mqqb0uhuTUd51rUohNgOuwELytrJTSWV-KWvL7aTjH8mjFldXLJ4Dhqj2FOSjZt00C7EvmVaGJIKWKvtj8oBmrNRB3VmolaM1EroFlErzb3uTuh_SfZQlgI764EXE48O4wqGYfeoHURTVY2uP_5_wWL2qE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68988095</pqid></control><display><type>article</type><title>Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Agtini, M.D. ; Ochiai, R.L. ; Soeharno, R. ; Lee, H.J. ; Sundoro, J. ; Hadinegoro, S.R. ; Han, O.P. ; Tana, L. ; Halim, F.X.S. ; Ghani, L. ; Delima ; Lestari, W. ; Sintawati, F.X. ; Kusumawardani, N. ; Malik, R. ; Santoso, T.S. ; Nadjib, M. ; Soeroso, S. ; Wangsasaputra, F. ; Ali, M. ; Ivanoff, B. ; Galindo, C.M. ; Pang, T. ; Clemens, J.D. ; Suwandono, A. ; Acosta, C.J.</creator><creatorcontrib>Agtini, M.D. ; Ochiai, R.L. ; Soeharno, R. ; Lee, H.J. ; Sundoro, J. ; Hadinegoro, S.R. ; Han, O.P. ; Tana, L. ; Halim, F.X.S. ; Ghani, L. ; Delima ; Lestari, W. ; Sintawati, F.X. ; Kusumawardani, N. ; Malik, R. ; Santoso, T.S. ; Nadjib, M. ; Soeroso, S. ; Wangsasaputra, F. ; Ali, M. ; Ivanoff, B. ; Galindo, C.M. ; Pang, T. ; Clemens, J.D. ; Suwandono, A. ; Acosta, C.J.</creatorcontrib><description>To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5°C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail. During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme. This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.</description><identifier>ISSN: 0033-3506</identifier><identifier>EISSN: 1476-5616</identifier><identifier>DOI: 10.1016/j.puhe.2006.06.008</identifier><identifier>PMID: 17005220</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject><![CDATA[Antigens, Bacterial - administration & dosage ; Antigens, Bacterial - adverse effects ; Child ; Feasibility Studies ; Humans ; Indonesia ; Mass vaccination ; Mass Vaccination - organization & administration ; Pilot Projects ; Polysaccharides, Bacterial - administration & dosage ; Polysaccharides, Bacterial - adverse effects ; Program Evaluation ; Refrigeration ; Safety ; Salmonella enterica - immunology ; School Health Services - organization & administration ; Students ; Typhoid fever ; Typhoid Fever - prevention & control ; Typhoid vi vaccine ; Typhoid-Paratyphoid Vaccines - administration & dosage ; Typhoid-Paratyphoid Vaccines - adverse effects ; Typhoid-Paratyphoid Vaccines - supply & distribution]]></subject><ispartof>Public health (London), 2006-11, Vol.120 (11), p.1081-1087</ispartof><rights>2006 The Royal Institute of Public Health</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-91da7e39ccf8736802161fef53b45f943a2dcb22a373b30cbeb3245dd608d253</citedby><cites>FETCH-LOGICAL-c354t-91da7e39ccf8736802161fef53b45f943a2dcb22a373b30cbeb3245dd608d253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.puhe.2006.06.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17005220$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agtini, M.D.</creatorcontrib><creatorcontrib>Ochiai, R.L.</creatorcontrib><creatorcontrib>Soeharno, R.</creatorcontrib><creatorcontrib>Lee, H.J.</creatorcontrib><creatorcontrib>Sundoro, J.</creatorcontrib><creatorcontrib>Hadinegoro, S.R.</creatorcontrib><creatorcontrib>Han, O.P.</creatorcontrib><creatorcontrib>Tana, L.</creatorcontrib><creatorcontrib>Halim, F.X.S.</creatorcontrib><creatorcontrib>Ghani, L.</creatorcontrib><creatorcontrib>Delima</creatorcontrib><creatorcontrib>Lestari, W.</creatorcontrib><creatorcontrib>Sintawati, F.X.</creatorcontrib><creatorcontrib>Kusumawardani, N.</creatorcontrib><creatorcontrib>Malik, R.</creatorcontrib><creatorcontrib>Santoso, T.S.</creatorcontrib><creatorcontrib>Nadjib, M.</creatorcontrib><creatorcontrib>Soeroso, S.</creatorcontrib><creatorcontrib>Wangsasaputra, F.</creatorcontrib><creatorcontrib>Ali, M.</creatorcontrib><creatorcontrib>Ivanoff, B.</creatorcontrib><creatorcontrib>Galindo, C.M.</creatorcontrib><creatorcontrib>Pang, T.</creatorcontrib><creatorcontrib>Clemens, J.D.</creatorcontrib><creatorcontrib>Suwandono, A.</creatorcontrib><creatorcontrib>Acosta, C.J.</creatorcontrib><title>Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform</title><title>Public health (London)</title><addtitle>Public Health</addtitle><description>To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5°C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail. During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme. This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.</description><subject>Antigens, Bacterial - administration &amp; dosage</subject><subject>Antigens, Bacterial - adverse effects</subject><subject>Child</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Indonesia</subject><subject>Mass vaccination</subject><subject>Mass Vaccination - organization &amp; administration</subject><subject>Pilot Projects</subject><subject>Polysaccharides, Bacterial - administration &amp; dosage</subject><subject>Polysaccharides, Bacterial - adverse effects</subject><subject>Program Evaluation</subject><subject>Refrigeration</subject><subject>Safety</subject><subject>Salmonella enterica - immunology</subject><subject>School Health Services - organization &amp; administration</subject><subject>Students</subject><subject>Typhoid fever</subject><subject>Typhoid Fever - prevention &amp; control</subject><subject>Typhoid vi vaccine</subject><subject>Typhoid-Paratyphoid Vaccines - administration &amp; dosage</subject><subject>Typhoid-Paratyphoid Vaccines - adverse effects</subject><subject>Typhoid-Paratyphoid Vaccines - supply &amp; distribution</subject><issn>0033-3506</issn><issn>1476-5616</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UV2r1DAQDaJ416t_wAfJk092nSRt2oIvcvFj5aIvF19Dmkxt1m5Sk3Rxf4z_1ZYt-CYcmGHmnAMzh5CXDPYMmHx73E_zgHsOIPcroHlEdqysZVFJJh-THYAQhahA3pBnKR0BgNeiekpuWA1QcQ478ufgcwx2Ns7_oN8dncJ4SdqYQUdnkebLNARnaY9njPS8LJxfpoFO0Z10vNBkhhBGagY32oieOk-_hpgH-kX_1DHrN_TgbfCY3NKenabaU_ztUkafN3HR6YR2M9fZBU-nUec-xNNz8qTXY8IXW70lDx8_PNx9Lu6_fTrcvb8vjKjKXLTM6hpFa0zf1EI2wJlkPfaV6Mqqb0uhuTUd51rUohNgOuwELytrJTSWV-KWvL7aTjH8mjFldXLJ4Dhqj2FOSjZt00C7EvmVaGJIKWKvtj8oBmrNRB3VmolaM1EroFlErzb3uTuh_SfZQlgI764EXE48O4wqGYfeoHURTVY2uP_5_wWL2qE0</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Agtini, M.D.</creator><creator>Ochiai, R.L.</creator><creator>Soeharno, R.</creator><creator>Lee, H.J.</creator><creator>Sundoro, J.</creator><creator>Hadinegoro, S.R.</creator><creator>Han, O.P.</creator><creator>Tana, L.</creator><creator>Halim, F.X.S.</creator><creator>Ghani, L.</creator><creator>Delima</creator><creator>Lestari, W.</creator><creator>Sintawati, F.X.</creator><creator>Kusumawardani, N.</creator><creator>Malik, R.</creator><creator>Santoso, T.S.</creator><creator>Nadjib, M.</creator><creator>Soeroso, S.</creator><creator>Wangsasaputra, F.</creator><creator>Ali, M.</creator><creator>Ivanoff, B.</creator><creator>Galindo, C.M.</creator><creator>Pang, T.</creator><creator>Clemens, J.D.</creator><creator>Suwandono, A.</creator><creator>Acosta, C.J.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform</title><author>Agtini, M.D. ; Ochiai, R.L. ; Soeharno, R. ; Lee, H.J. ; Sundoro, J. ; Hadinegoro, S.R. ; Han, O.P. ; Tana, L. ; Halim, F.X.S. ; Ghani, L. ; Delima ; Lestari, W. ; Sintawati, F.X. ; Kusumawardani, N. ; Malik, R. ; Santoso, T.S. ; Nadjib, M. ; Soeroso, S. ; Wangsasaputra, F. ; Ali, M. ; Ivanoff, B. ; Galindo, C.M. ; Pang, T. ; Clemens, J.D. ; Suwandono, A. ; Acosta, C.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-91da7e39ccf8736802161fef53b45f943a2dcb22a373b30cbeb3245dd608d253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antigens, Bacterial - administration &amp; dosage</topic><topic>Antigens, Bacterial - adverse effects</topic><topic>Child</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Indonesia</topic><topic>Mass vaccination</topic><topic>Mass Vaccination - organization &amp; administration</topic><topic>Pilot Projects</topic><topic>Polysaccharides, Bacterial - administration &amp; dosage</topic><topic>Polysaccharides, Bacterial - adverse effects</topic><topic>Program Evaluation</topic><topic>Refrigeration</topic><topic>Safety</topic><topic>Salmonella enterica - immunology</topic><topic>School Health Services - organization &amp; administration</topic><topic>Students</topic><topic>Typhoid fever</topic><topic>Typhoid Fever - prevention &amp; control</topic><topic>Typhoid vi vaccine</topic><topic>Typhoid-Paratyphoid Vaccines - administration &amp; dosage</topic><topic>Typhoid-Paratyphoid Vaccines - adverse effects</topic><topic>Typhoid-Paratyphoid Vaccines - supply &amp; distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agtini, M.D.</creatorcontrib><creatorcontrib>Ochiai, R.L.</creatorcontrib><creatorcontrib>Soeharno, R.</creatorcontrib><creatorcontrib>Lee, H.J.</creatorcontrib><creatorcontrib>Sundoro, J.</creatorcontrib><creatorcontrib>Hadinegoro, S.R.</creatorcontrib><creatorcontrib>Han, O.P.</creatorcontrib><creatorcontrib>Tana, L.</creatorcontrib><creatorcontrib>Halim, F.X.S.</creatorcontrib><creatorcontrib>Ghani, L.</creatorcontrib><creatorcontrib>Delima</creatorcontrib><creatorcontrib>Lestari, W.</creatorcontrib><creatorcontrib>Sintawati, F.X.</creatorcontrib><creatorcontrib>Kusumawardani, N.</creatorcontrib><creatorcontrib>Malik, R.</creatorcontrib><creatorcontrib>Santoso, T.S.</creatorcontrib><creatorcontrib>Nadjib, M.</creatorcontrib><creatorcontrib>Soeroso, S.</creatorcontrib><creatorcontrib>Wangsasaputra, F.</creatorcontrib><creatorcontrib>Ali, M.</creatorcontrib><creatorcontrib>Ivanoff, B.</creatorcontrib><creatorcontrib>Galindo, C.M.</creatorcontrib><creatorcontrib>Pang, T.</creatorcontrib><creatorcontrib>Clemens, J.D.</creatorcontrib><creatorcontrib>Suwandono, A.</creatorcontrib><creatorcontrib>Acosta, C.J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Public health (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agtini, M.D.</au><au>Ochiai, R.L.</au><au>Soeharno, R.</au><au>Lee, H.J.</au><au>Sundoro, J.</au><au>Hadinegoro, S.R.</au><au>Han, O.P.</au><au>Tana, L.</au><au>Halim, F.X.S.</au><au>Ghani, L.</au><au>Delima</au><au>Lestari, W.</au><au>Sintawati, F.X.</au><au>Kusumawardani, N.</au><au>Malik, R.</au><au>Santoso, T.S.</au><au>Nadjib, M.</au><au>Soeroso, S.</au><au>Wangsasaputra, F.</au><au>Ali, M.</au><au>Ivanoff, B.</au><au>Galindo, C.M.</au><au>Pang, T.</au><au>Clemens, J.D.</au><au>Suwandono, A.</au><au>Acosta, C.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform</atitle><jtitle>Public health (London)</jtitle><addtitle>Public Health</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>120</volume><issue>11</issue><spage>1081</spage><epage>1087</epage><pages>1081-1087</pages><issn>0033-3506</issn><eissn>1476-5616</eissn><abstract>To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta. Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5°C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail. During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme. This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>17005220</pmid><doi>10.1016/j.puhe.2006.06.008</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3506
ispartof Public health (London), 2006-11, Vol.120 (11), p.1081-1087
issn 0033-3506
1476-5616
language eng
recordid cdi_proquest_miscellaneous_68988095
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Antigens, Bacterial - administration & dosage
Antigens, Bacterial - adverse effects
Child
Feasibility Studies
Humans
Indonesia
Mass vaccination
Mass Vaccination - organization & administration
Pilot Projects
Polysaccharides, Bacterial - administration & dosage
Polysaccharides, Bacterial - adverse effects
Program Evaluation
Refrigeration
Safety
Salmonella enterica - immunology
School Health Services - organization & administration
Students
Typhoid fever
Typhoid Fever - prevention & control
Typhoid vi vaccine
Typhoid-Paratyphoid Vaccines - administration & dosage
Typhoid-Paratyphoid Vaccines - adverse effects
Typhoid-Paratyphoid Vaccines - supply & distribution
title Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T22%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Introducing%20Vi%20polysaccharide%20typhoid%20fever%20vaccine%20to%20primary%20school%20children%20in%20North%20Jakarta,%20Indonesia,%20via%20an%20existent%20school-based%20vaccination%20platform&rft.jtitle=Public%20health%20(London)&rft.au=Agtini,%20M.D.&rft.date=2006-11-01&rft.volume=120&rft.issue=11&rft.spage=1081&rft.epage=1087&rft.pages=1081-1087&rft.issn=0033-3506&rft.eissn=1476-5616&rft_id=info:doi/10.1016/j.puhe.2006.06.008&rft_dat=%3Cproquest_cross%3E68988095%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68988095&rft_id=info:pmid/17005220&rft_els_id=S0033350606001661&rfr_iscdi=true